Core Viewpoint - Adma Biologics has shown strong stock performance recently, with a +17.7% return over the past month, contrasting with the S&P 500's -0.7% change, indicating potential investor interest and market momentum [2]. Earnings Estimate Revisions - The consensus earnings estimate for Adma Biologics is $0.16 per share for the current quarter, reflecting a year-over-year increase of +100% [5]. - For the current fiscal year, the consensus earnings estimate stands at $0.71, indicating a year-over-year change of +44.9% [5]. - The next fiscal year's consensus earnings estimate is $0.93, representing a +31% change from the previous year [6]. - The Zacks Rank for Adma Biologics is 2 (Buy), suggesting a favorable outlook based on earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $119.1 million, indicating a year-over-year increase of +45.5% [11]. - For the current fiscal year, the sales estimate is $495.8 million, reflecting a +16.3% change, while the next fiscal year's estimate is $611.5 million, indicating a +23.3% change [11]. Last Reported Results and Surprise History - In the last reported quarter, Adma Biologics generated revenues of $117.55 million, a year-over-year increase of +59.1% [12]. - The EPS for the same period was $0.14, compared to $0.04 a year ago, with a revenue surprise of +4.77% against the Zacks Consensus Estimate [12]. - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped revenue estimates each time [13]. Valuation - Adma Biologics has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [17].

Market Overview - Wall Street has experienced significant volatility in 2025, with all three major stock indexes (Dow, S&P 500, Nasdaq Composite) in negative territory year to date [1] - Small-cap benchmarks (Russell 2000, S&P 600) and mid-cap-specific S&P 400 Index are also in the red year to date [1] High-Performing Mid-Cap Stocks - Despite market headwinds, five mid-cap stocks have provided over 25% returns year to date: ADMA Biologics Inc. (ADMA), FirstCash Holdings Inc. (FCFS), Stride Inc. (LRN), Life Time Group Holdings Inc. (LTH), and National Fuel Gas Co. (NFG) [2] - These stocks exhibit strong revenue and earnings growth potential for 2025, with positive earnings estimate revisions over the last 60 days [3] ADMA Biologics Inc. - ADMA Biologics specializes in plasma-based biologics for treating and preventing infectious diseases, targeting immune-compromised individuals [7][8] - Expected revenue growth rate is 16.3% and earnings growth rate is 44.9% for the current year, with a 2.9% improvement in earnings estimates over the last 60 days [9] FirstCash Holdings Inc. - FirstCash operates retail pawn stores across the U.S., Mexico, and Latin America, providing loans against personal property and retailing forfeited merchandise [10][11] - Expected revenue growth rate is 0.2% and earnings growth rate is 17.2% for the current year, with a 2.6% improvement in earnings estimates over the last seven days [13] Stride Inc. - Stride is a technology-based education service company offering online curriculum and educational services [14] - Expected revenue growth rate is 14.9% and earnings growth rate is 48.4% for the current year, with a 4.3% improvement in earnings estimates over the last 30 days [16] Life Time Group Holdings Inc. - Life Time provides health, fitness, and wellness experiences, operating various fitness and recreation centers [17][18] - Expected revenue growth rate is 12.9% and earnings growth rate is 37.9% for the current year, with a 6.5% improvement in earnings estimates over the last 60 days [19] National Fuel Gas Co. - National Fuel Gas focuses on systematic investments to strengthen operations and reduce emissions, with significant capital investments planned [20][21] - Expected revenue growth rate is 31.5% and earnings growth rate is 39.1% for the current year, with a 1.9% improvement in earnings estimates over the last 60 days [22][23]

Core Viewpoint - ADMA Biologics, Inc. is set to report its first quarter 2025 financial results on May 7, 2025, and will host a conference call to discuss these results and other company updates [1]. Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM®, and NABI-HB® [3]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia [3]. - The company operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, which collects source plasma for its products [3]. - ADMA holds numerous U.S. and foreign patents related to its products and candidates [3].

Core Insights - ADMA Biologics, Inc. has received U.S. FDA approval for an innovative yield enhancement production process, which is expected to increase production yields by approximately 20% from the same starting plasma volume [1][2] - This approval is anticipated to significantly accelerate the company's revenue and earnings trajectory starting in late 2025 and continuing into 2026 and beyond [2] - ADMA is the first U.S. producer of plasma-derived products to achieve regulatory approval for this innovative process, showcasing its leadership in modernizing plasma fractionation [2] Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3] - The company currently markets three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM®, and NABI-HB® [3] - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia, demonstrating its commitment to product and process innovation [3] Production and R&D Capabilities - The innovative yield enhancement process is expected to benefit both ASCENIV and BIVIGAM, enhancing production output capacity [1] - ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, that collects source plasma for its products [3] - The company holds numerous U.S. and foreign patents related to its products and product candidates, reinforcing its competitive position in the market [3]

Group 1 - Adma Biologics (ADMA) closed at $21.31, with a +0.38% change from the previous day, outperforming the S&P 500's gain of 0.13% [1] - Over the past month, ADMA shares have appreciated by 3.01%, while the Medical sector lost 8.46% and the S&P 500 lost 6.3% [1] Group 2 - The upcoming financial results for Adma Biologics are anticipated to show an EPS of $0.16, reflecting a 100% increase from the same quarter last year [2] - Revenue is forecasted to be $119.1 million, indicating a growth of 45.46% compared to the corresponding quarter of the prior year [2] Group 3 - Full-year Zacks Consensus Estimates predict earnings of $0.71 per share and revenue of $495.8 million, representing year-over-year changes of +44.9% and +16.26%, respectively [3] - Recent adjustments to analyst estimates for Adma Biologics indicate positive sentiment regarding the company's business and profitability [3] Group 4 - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that stocks rated 1 deliver an average annual return of +25% since 1988 [5] - Over the past month, the Zacks Consensus EPS estimate for Adma Biologics has increased by 2.16%, and the company currently holds a Zacks Rank of 2 (Buy) [5] Group 5 - Adma Biologics has a Forward P/E ratio of 29.9, which is a premium compared to the industry average Forward P/E of 15.68 [6] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 76, placing it in the top 31% of over 250 industries [6]

Core Viewpoint - Adma Biologics (ADMA) is showing potential for investment due to its recent technical indicators and positive earnings revisions, suggesting a bullish trend ahead [1][4][5] Technical Analysis - ADMA has crossed above the 20-day moving average, indicating a short-term bullish trend [1] - The 20-day simple moving average is favored by traders for its ability to smooth out price fluctuations and signal trend reversals [1][2] Performance Metrics - Over the past four weeks, ADMA's stock has increased by 12% [4] - The company currently holds a Zacks Rank 2 (Buy), indicating strong potential for further price appreciation [4] Earnings Estimates - In the last two months, there have been two upward revisions in earnings estimates for the current fiscal year, with no downward revisions [4] - The consensus earnings estimate has also seen an increase, reinforcing the positive outlook for ADMA [4][5]

Company Overview - Adma Biologics (ADMA) shares increased by 7.8% to close at $20.91, driven by notable trading volume and broader market optimism [1] - The stock has gained 5.3% over the past four weeks, indicating strong fundamentals [1] Earnings Expectations - Adma Biologics is expected to report quarterly earnings of $0.16 per share, reflecting a year-over-year increase of 100% [2] - Revenue projections stand at $119.1 million, which is a 45.5% increase compared to the same quarter last year [2] Stock Performance and Trends - The consensus EPS estimate for Adma Biologics has remained unchanged over the last 30 days, suggesting that the stock's price movement may not sustain without earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 2 (Buy), indicating positive market sentiment [3] Industry Comparison - Adma Biologics operates within the Zacks Medical - Biomedical and Genetics industry, where Blueprint Medicines (BPMC) has seen a 2.1% increase to $82.53, but has returned -9.8% over the past month [3] - Blueprint Medicines has a consensus EPS estimate of -$0.41, which is a 15.4% change over the past month and a 68.9% change from the previous year [4]

Core Viewpoint - ADMA Biologics (ADMA) shows significant upside potential with a mean price target of $27.33, indicating a 51.8% increase from the current trading price of $18.01 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $4.04, where the lowest estimate of $25 suggests a 38.8% increase, and the highest estimate of $32 indicates a potential surge of 77.7% [2] - A low standard deviation among price targets suggests strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [8] Earnings Estimates and Analyst Sentiment - Analysts exhibit growing optimism about ADMA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [10] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.2%, with one estimate moving higher and no negative revisions [11] - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, further supporting the stock's potential upside [12]

Core Viewpoint - ADMA Biologics, Inc. emphasizes its strategic advantage due to fully U.S.-based manufacturing and supply chain operations, which are insulated from recent tariffs on foreign goods [1][2]. Group 1: Company Overview - ADMA Biologics is a biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM®, and NABI-HB®, targeting immune deficiencies and hepatitis B [3]. - ADMA operates an FDA-licensed facility in Boca Raton, Florida, for the production of its immune globulin products and also runs FDA-approved source plasma collection through its subsidiary, ADMA BioCenters [3]. Group 2: Strategic Positioning - The company asserts that the tariffs on foreign goods will not affect its supply chain or production operations due to its fully integrated U.S.-based supply chain [2]. - ADMA's operational model ensures enhanced supply chain robustness, resilience, and regulatory compliance, aligning with federal and private sector preferences for U.S.-made products [2]. - By maintaining complete operational control within the U.S., ADMA is positioned to leverage national economic incentives and provide reliable, high-quality offerings to its domestic customers [2].

Technical Analysis - ADMA Biologics Inc has reached a key level of support, with its 50-day simple moving average crossing above the 200-day simple moving average, indicating a "golden cross" [1] - A golden cross is a bullish technical chart pattern that suggests a potential breakout, formed when a stock's short-term moving average surpasses its long-term moving average [1][2] Market Performance - ADMA has experienced a rally of 31% over the past four weeks, indicating strong upward momentum [3] - The company currently holds a 2 (Buy) rating on the Zacks Rank, suggesting positive market sentiment [3] Earnings Outlook - The earnings outlook for ADMA is positive, with no earnings estimates decreasing in the past two months and two revisions higher, leading to an increase in the Zacks Consensus Estimate [3] - This positive earnings outlook further solidifies the bullish case for ADMA [3] Investment Consideration - Investors are encouraged to consider adding ADMA to their watchlist due to the significant technical indicator and the positive movement in earnings estimates [4]